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Introduction 
Treatment by All-trans retinoic acid (ATRA) followed by 
anthracycline-AraC chemotherapy has improved the outcome 
of acute promyelocytic leukemia.1) ATRA is usually well tol-
erated, but a few major side effects can be observed.2-4) Retino-
ic acid syndrome (RAS) often occurs during the induction 
chemotherapy of acute promyelocytic leukemia. In RAS, 
myocarditis has been rarely documented. We reports a very 
rare case of fully recovered myocarditis as a result of RAS re-
lated to ATRA administration during induction treatment of 
acute promyelocytic leukemia which documented by echocar-
diographic evidence.
Case
A 39-year-old woman was admitted to our hospital due to 
dyspnea and dizziness. The patient had been well until ap-
proximately 8 weeks earlier, when dyspnea and dizziness de-
veloped. She was physically active and did not have a history 
of hypertension, diabetes, hospitalizations, surgical proce-
dures, or allergic reactions to drugs. She was taking no medi-
cations at the time of the admission. 
On physical examination, she appeared in acute distress. The 
blood pressure and heart rate were 130/80 mmHg, 84 beats 
per minute, each other, and the respiratory rate 20 breaths per 
minute. The physical examination of the head, ears, eyes, nose, 
and throat were otherwise normal. No lymph node was palpa-
ble in the cervical, axillary, and inguinal regions. The lungs 
and heart were normal on auscultation except functional systol-
ic murmur. The abdomen was softly palpated with normal 
bowel sounds. There is no hepatosplenomegaly. The genitouri-
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nary, cutaneous, and neurologic examinations were normal, as 
was examination of his arms and legs.
The initial complete blood counts showed hemoglobin of 
3.3 g/dL; white blood cell count of 2.16 × 109/L; platelets 
count of 18 × 109/L. Examination of the peripheral-blood 
smear revealed pancytopenia and a few immature cells with 
Auer rods. Examination of the biopsy specimen showed that 
the bone marrow was hypercellular (> 95%) and replaced by 
abnormal large cells with Auer rods and cytoplasmic dense 
large granules. On the smear of the aspirate, 57% of the cells 
were promyelocytes and 2.6% were myeloblasts. On cyto-
chemical staining, the promyelocytes were positive for myelo-
peroxidase, Sudan Black B stain and Periodic Acid stain. An 
abnormal karyotype, t (15;17) (q22;q12), was identified. Real-
timepolymerase chain reaction (PCR) revealed a promyelocyt-
ic leukemia-retinoic acid receptor α (PML/RARa) rearrange-
ment. She was finally diagnosed with acute promyelocytic 
leukemia.
She received induction therapy (ATRA 45 mg/m2 from day 
1 to complete remission, and idarubicin 12 mg/m2 IV on day 
2, 4, 6 and 8) and supportive therapy with platelet and plasma 
transfusion. Screening echocardiography was performed before 
induction therapy and showed normal wall motions and 60% 
of ejection fraction.
No complication was observed until 17 day from the start 
of induction therapy. However, the patient complained mild 
chest pain and dyspnea on day 18 and febrile sense on day 20. 
Blood pressure was 110/70 mmHg and pulse rate was 120 
Fig. 1. Left ventricular (LV) systolic and diastolic dysfunction at retinoic acid syndrome attack. A: Decreased LV systolic function (LV ejection fraction 
38%) by LV M-mode. B: Abnormal LV diastolic function (E/Em 13.4) - restrictive LV ventricular filling. LVEDD: LV end systolic diameter, LVESD: LV end 
systolic diameter, LVEF: left ventricular ejection fraction, E: early diastolic mitral inflow velocity, Em: early diastolic mitral tissue Doppler velocity.
Fig. 2. The change of left ventricular (LV) global radial strain at LV mid wall. Comparing baseline LV global radial strain, global radial strain at RAS was 
decreased -19.2% to -14.5% and color-coded strain pattern form anterior to lateral segmental at mid LV wall was decreased. RAS: retinoic acid 
syndrome.
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beats per minute. But body temperature was 40.2°C. Physical 
examination showed no abnormalities except mild pretibial 
pitting edema. The electrocardiogram revealed low QRS am-
plitudes without newly developed Q wave or ST segment 
change. Laboratory findings showed a white blood cell count 
of 1.06 × 109/L, a creatine kinase of 52 IU/L (21-232), CK-
MB of 2.5 ng/mL (0.0-5.0), a brain natriuretic peptide of 
1430 pg/mL (0-100), Troponin-I of 2.39 ng/mL (0.0-0.05), 
and positive Troponin-T 0.14 ng/mL (0.0-0.03). The echocar-
diography revealed decreased LV systolic function (left ven-
tricular ejection fraction 38%) with mildly enlarged LV 
chamber size (56/43 mm), increased left atrial volume index 
(36.9 mL/m2) and moderate mitral and tricuspid regurgita-
tion (grade II). Diastolic property was restrictive LV filling 
pattern (mitral E velocity 1.07 m/s, mitral A velocity 0.42 m/s, 
deceleration time,125 ms, EA ratio; 2.59) and E/Em was ele-
vated (13.4) (Fig. 1). The anterior base to mid segment of left 
ventricular wall showed severe hypokinetic motion. LV apex 
and lateral and inferior wall thickening were normal. Compar-
ing baseline LV global radial strain, global radial strain was   
decreased -19.2% into -14.5% and color-coded strain pattern 
form anterior to lateral segmental at mid LV wall was de-
creased (Fig. 2). 64-channel Multidetector CT-coronary Angi-
ography for exclusion of ischemic coronary artery disease re-
vealed that there was no significant obstructive epicardial 
coronary artery disease or anatomic variances (Fig. 3).  
All blood, sputum, urine cultures were negative. A diagno-
sis of RAS was made on day 22 because of pretibial pitting 
edema, mild chest pain with dyspnea and unexplained fever 
(40.2°C). ATRA was discontinued while dexamethasone and 
diuretics were administered. In the following days, fever was 
disappeared and the patient symptoms were disappeared. Echo-
cardiography repeated on day 37 (when the patient was fully 
recovered) revealed normalized chamber size of left ventricle 
and left atrium. LV systolic function and diastolic function 
was normalized without wall motion abnormality. ATRA was 
reintroduced in the following three cycles of consolidation 
chemotherapy without complication. The patient achieved 
molecular complete remission after induction therapy, which 
was sustained through the consolidation therapy. 
Discussion 
ATRA has a central role in the treatment of acute promy-
elocytic leukemia because addition of ATRA to anthracyclines 
has been shown to improve disease-free survival and overall 
survival compared to chemotherapy alone.1) Since the promy-
elocytic leukemia-retinoic acid receptor fusion gene product 
that is resulted from the balanced translocation t (15;17), char-
acteristic for acute promyelocytic leukemia, has a unique sensi-
tivity to ATRA, ATRA induces the differentiation of leuke-
mic promyelocytes into mature cells. 
Though ATRA therapy is considered to be safe and cause 
mild adverse effects, it can be complicated severely by the 
RAS, which was first documented by Frankel et al.2) RAS oc-
curs in up to 25% of patients treated with ATRA.1)3) 
The RAS is characterized by development of fever, pulmo-
nary infiltrates and effusions, pericardial effusions, hypoten-
sion, dyspnea, and renal dysfunction. The morbidity and mor-
tality of RAS is significant and reported mortality rate was as 
high as 9%. 
Fig. 3. 64 channel multidetecter CT coronary angiography show no significant obstructive epicardial coronary artery disease.Journal of Cardiovascular Ultrasound 19 | June  2011
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The diagnosis of RAS is by at least three of the followings: 
weight gain, respiratory distress, unexplained fever, interstitial 
pulmonary infiltrates, pleural or pericardial effusions. In pa-
tient described above, she was diagnosed as RAS because of 
pretibial pitting edema, mild chest pain and dyspnea and un-
explained fever (40.2°C). And the patient’s clinical symptoms 
and signs ware disappeared after discontinuation of ATRA 
and there was no recurrence of symptoms after ATRA resum-
ing. The stress induced cardiomyopathy was ruled out because 
of there were no evidence of newly developed electrocardio-
graphic abnormalities despite transient left ventricular wall 
motion abnormalities and absence of obstructive coronary ar-
tery disease. 
The pathogenesis of the ATRA syndrome is not yet fully 
understood, but it is thought to be due to leukocyte infiltra-
tion and cytokine release causing endothelial damage and ex-
travasation of APL cells upon maturation induction by ATRA 
treatment.4) Common cardiac manifestation of RAS is pericar-
dial effusion (19%) and fatal pericardial tamponade may be 
occur.5)6) But myocarditis is rare complication. To our knowl-
edge, only four cases of ATRA-induced generalized myocardi-
tis with cardiac involvement has been reported.7-10) In our case, 
patient had symptoms of myocarditis with laboratory evi-
dence of elevated b-type natriuretic peptide level and transient 
cardiac troponin after induction of ATRA treatment. The evi-
dence for myocarditis-transient reversible LV dysfunction was 
also documented by echocardiogram. 
In conclusion, we present a case of ATRA-induced, myocar-
ditis that was diagnosed by serologic and echocardiographic 
evidence. The patient recovered completely without sequale 
and was subsequently retreated with ATRA without recur-
rence of the myocarditis.
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